SSelectStock

ANTHEMAnthem Biosciences Limited

Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

₹822.25
▲ 1.16%
51Average

Mkt Cap
₹46,140 Cr
P/E
81.2
P/B
15.1
Div Yield
0.23%
52W High
₹977.55
52W Low
₹577.64

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)46,139.80
P/E81.17
P/B15.08
PEG—
ROE %19.50
ROCE %22.80
Debt / Equity0.02
EPS10.13
Revenue Growth %-22.60
Profit Growth %-12.80
Dividend Yield %0.23
Promoter Holding %84.18
FII Holding %12.34
DII Holding %—
Beta0.71

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

AVOIDConviction 58%

Why avoid

  • • A bearish pattern is active and overall evidence is mixed
  • • Revenue growth: -22.6% YoY
  • • Profit growth: -12.8% YoY
  • • RSI: 40
  • • MACD: bearish
  • • Double Top bearish signal (setup quality 67%)

Bull case

  • • ROE: 19.5%
  • • ROCE: 22.8%
  • • Debt/Equity: 0.02
  • • Price vs SMA200: above

Bear case

  • • Revenue growth: -22.6% YoY
  • • Profit growth: -12.8% YoY
  • • RSI: 40
  • • MACD: bearish

Key risks

  • • Revenue growth: -22.6% YoY
  • • Profit growth: -12.8% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹822.25
Stop Loss
₹775.52
risk 5.7%
Target 1 (1.5R)
₹892.35
+8.5%
Target 2 (3R)
₹962.45
+17.1%
Support (20d)
₹783.35
Resistance (52w)
₹977.55
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹46.73/share
ATR (volatility)
₹26.76
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹26.76). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental49
Technical38
Momentum47
Risk (safety)83

Peers — Pharma

SHUKRAPHAR▲ 4.65%
73
LAURUSLABS▲ 4.51%
70
JBCHEPHARM 0.00%
70
ZYDUSLIFE▲ 2.74%
68
IPCALAB▼ 0.75%
66
CORONA▼ 0.47%
65